Skip to main content
. 2015 May 4;100(7):2621–2629. doi: 10.1210/jc.2015-1531

Figure 2.

Figure 2.

During sitagliptin administration to cART-treated HIV+ adults with IGT (n = 18), the reductions in plasma CXCL10 (P = .008) at weeks 4 and 8 (A) and hsCRP concentrations (P = .006) at week 8 (B) were greater than in the placebo group (n = 18). Bars represent mean ± SE. Symbols and lines represent results for individual participants.